Charles Greg Guyer is CTO & VP at BIOMARIN PHARMACEUTICAL INC (BMRN). They have made 5 open-market trades across 1 company since 2022, most recently 2026-03-17.
CIK 0001811096
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BMRN | 84,140 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BMRN | SELL | 2026-03-11 | 2026-03-12 | $60.46 | $997K | -8.6% | -7.3% | -5.2% |
| BMRN | SELL | 2025-03-06 | 2025-03-07 | $71.28 | $1.0M | -2.1% | -18.8% | -24.1% |
| BMRN | SELL | 2024-11-12 | 2024-11-14 | $66.37 | $701K | -1.8% | -0.8% | -0.3% |
| BMRN | SELL | 2023-08-09 | 2023-08-10 | $93.30 | $500K | -0.0% | +0.3% | -5.6% |
| BMRN | SELL | 2022-08-08 | 2022-08-10 | $96.56 | $1.2M | -3.3% | -2.8% | -15.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.